[go: up one dir, main page]

DE60319084D1 - Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz - Google Patents

Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz

Info

Publication number
DE60319084D1
DE60319084D1 DE60319084T DE60319084T DE60319084D1 DE 60319084 D1 DE60319084 D1 DE 60319084D1 DE 60319084 T DE60319084 T DE 60319084T DE 60319084 T DE60319084 T DE 60319084T DE 60319084 D1 DE60319084 D1 DE 60319084D1
Authority
DE
Germany
Prior art keywords
ortho
treatment
benzoic acid
acid derivatives
insulin resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60319084T
Other languages
English (en)
Other versions
DE60319084T2 (de
Inventor
Lanna Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201935A external-priority patent/SE0201935D0/xx
Priority claimed from SE0203826A external-priority patent/SE0203826D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60319084D1 publication Critical patent/DE60319084D1/de
Publication of DE60319084T2 publication Critical patent/DE60319084T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
DE60319084T 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz Expired - Lifetime DE60319084T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0201935 2002-06-20
SE0201935A SE0201935D0 (sv) 2002-06-20 2002-06-20 Therapeutic agents
SE0203826A SE0203826D0 (sv) 2002-12-20 2002-12-20 Therapeutic agents
SE0203826 2002-12-20
PCT/GB2003/002584 WO2004000790A1 (en) 2002-06-20 2003-06-17 Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance

Publications (2)

Publication Number Publication Date
DE60319084D1 true DE60319084D1 (de) 2008-03-27
DE60319084T2 DE60319084T2 (de) 2009-01-29

Family

ID=30002442

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60319084T Expired - Lifetime DE60319084T2 (de) 2002-06-20 2003-06-17 Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz

Country Status (22)

Country Link
US (1) US7355069B2 (de)
EP (1) EP1517883B8 (de)
JP (2) JP3782818B2 (de)
KR (1) KR20050014013A (de)
CN (1) CN1319938C (de)
AR (1) AR039713A1 (de)
AT (1) ATE386013T1 (de)
AU (1) AU2003240099B2 (de)
BR (1) BR0311932A (de)
CA (1) CA2489834C (de)
DE (1) DE60319084T2 (de)
DK (1) DK1517883T3 (de)
ES (1) ES2299702T3 (de)
IL (1) IL165671A0 (de)
IS (1) IS7627A (de)
MX (1) MXPA04012686A (de)
NO (1) NO20045353L (de)
PL (1) PL375074A1 (de)
PT (1) PT1517883E (de)
RU (1) RU2004137094A (de)
TW (1) TWI282784B (de)
WO (1) WO2004000790A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576131B2 (en) 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
FR2875805B1 (fr) * 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
GB0522431D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Chemical process
GB0522433D0 (en) * 2005-11-03 2005-12-14 Astrazeneca Ab Therapeutic agents

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK148576A (da) 1975-04-18 1976-10-19 Boehringer Mannheim Gmbh Fenylalkankarbonsyrederivater og fremgangsmade til deres fremstilling
DE19615263A1 (de) 1996-04-18 1997-10-23 Bayer Ag Benzyloxy-substituierte Phenylglycinolamide
EP1030665A4 (de) 1997-10-17 2002-11-27 Aventis Pharm Prod Inc Therapeutische verwendungen von chinolin derivate
NZ503809A (en) 1997-12-19 2002-04-26 Schering Ag Ortho-anthranilamide derivatives as anti-coagulants
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
GB9822473D0 (en) 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds
DE60027420T2 (de) 1999-04-28 2006-11-16 Aventis Pharma Deutschland Gmbh Tri-aryl-säurederivate als ppar rezeptor liganden
DK1177187T3 (da) 1999-04-28 2007-10-15 Sanofi Aventis Deutschland Diarylsyrederivater som PPAR-receptorligander
JP4618845B2 (ja) * 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US6509374B2 (en) 2000-04-17 2003-01-21 Novo Nordisk A/S Compounds, their preparation and use
SE0003766D0 (sv) 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0116955D0 (en) 2001-07-11 2001-09-05 Syngenta Ltd Weed control process
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1582151A (zh) 2001-09-08 2005-02-16 阿斯特拉曾尼卡有限公司 用于治疗高脂血症、具有回肠胆汁酸转运(ibat)抑制活性的苯并硫氮杂䓬和苯并硫杂二氮杂䓬衍生物
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
SE0201937D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
SE0201936D0 (sv) 2002-06-20 2002-06-20 Astrazeneca Ab Therapeutic agents
US7351858B2 (en) 2002-06-20 2008-04-01 Astrazeneca Ab Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314078D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314136D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314131D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314130D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314075D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314260D0 (en) 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
AU2003240099A1 (en) 2004-01-06
US7355069B2 (en) 2008-04-08
CA2489834A1 (en) 2003-12-31
AR039713A1 (es) 2005-03-09
JP2005529970A (ja) 2005-10-06
DE60319084T2 (de) 2009-01-29
IS7627A (is) 2005-01-05
JP3782818B2 (ja) 2006-06-07
JP2006182782A (ja) 2006-07-13
US20050256198A1 (en) 2005-11-17
EP1517883A1 (de) 2005-03-30
PL375074A1 (en) 2005-11-14
CN1319938C (zh) 2007-06-06
BR0311932A (pt) 2005-03-22
RU2004137094A (ru) 2005-08-10
MXPA04012686A (es) 2005-03-23
TW200409747A (en) 2004-06-16
KR20050014013A (ko) 2005-02-05
NO20045353L (no) 2005-01-20
TWI282784B (en) 2007-06-21
ATE386013T1 (de) 2008-03-15
AU2003240099B2 (en) 2007-02-01
EP1517883B1 (de) 2008-02-13
ES2299702T3 (es) 2008-06-01
DK1517883T3 (da) 2008-05-26
HK1073838A1 (en) 2005-10-21
CN1675171A (zh) 2005-09-28
PT1517883E (pt) 2008-04-21
IL165671A0 (en) 2006-01-15
CA2489834C (en) 2006-10-03
EP1517883B8 (de) 2008-05-21
WO2004000790A1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE60320007D1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
DE60303238D1 (de) Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60030109D1 (de) (-)(3-trihalomethylphenoxy) (4-halophenyl) zur behandlung von insulinresistenz und typ ii diabetes
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
ATE476414T1 (de) Biphenyloxyessigsäurederivate zur behandlung von atemwegserkrankungen
ATE273304T1 (de) (s)-4-amino-5-chloro-2-methoxy-n-(1-(1-(2- tetrahydrofuryl-carbonyl)-4-piperidinylmethyl)- - piperidinyl)benzamid zur behandlung von magen- darmbewegungskrankheiten
NO20045554L (no) Fremgangsmate for behandling av diabetes
ATE438623T1 (de) Aroyl-o-piperidinderivate zur behandlung von problemen im zusammenhang mit diabetes
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
EP1651237A4 (de) Verfahren zur behandlung von dermatologischen erkrankungen
ATE386013T1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE385790T1 (de) Ortho-substituierte benzoesäurederivate zur behandlung von insulinresistenz
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602004007546D1 (de) Verwendung von pentadiensäure-derivaten zur behandlung von hyperurikämie
ATE359270T1 (de) Phenyl-piperidin-4-yliden-methyl-benzamidderiva e zur behandlung von schmerz oder magen-darm- erkrankungen
DE602004015272D1 (de) Verwendung von phenoxyessigsäurederivaten zur behandlung der hyperaktiven blase

Legal Events

Date Code Title Description
8364 No opposition during term of opposition